Jyan-Gwo Joseph Su Selected Research

Neoplasms (Cancer)

1/2022	Sorafenib is an antagonist of the aryl hydrocarbon receptor.
1/2016	Activation of aryl hydrocarbon receptor reduces carbendazim-induced cell death.
2/2014	AKT mediates actinomycin D-induced p53 expression.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Jyan-Gwo Joseph Su Research Topics

Disease

3	Neoplasms (Cancer) 01/2022 - 02/2014
3	Hepatocellular Carcinoma (Hepatoma) 01/2022 - 02/2013
1	Inflammation (Inflammations) 11/2023
1	Pain (Aches) 11/2023
1	Fever (Fevers) 11/2023
1	Prostatic Neoplasms (Prostate Cancer) 01/2021
1	Carcinoma (Carcinomatosis) 01/2016

Drug/Important Bio-Agent (IBA)

1	EtoricoxibIBA 11/2023
1	Non-Steroidal Anti-Inflammatory Agents (NSAIDs)IBA 11/2023
1	Sorafenib (BAY 43-9006)FDA Link 01/2022
1	Glucocorticoid Receptors (Glucocorticoid Receptor)IBA 01/2021
1	carbendazimIBA 01/2016
1	Cytochrome P-450 Enzyme System (Cytochrome P450)IBA 02/2013
1	cyprodinilIBA 02/2013
1	Cytochrome P-450 CYP1A1 (CYP1A1)IBA 02/2013

Therapy/Procedure

1	Castration 01/2021
1	Drug Therapy (Chemotherapy) 01/2016
1	Therapeutics 02/2014